Literature DB >> 22291034

Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis.

Kelly Claire Simon1, Eilis J O'Reilly, Kassandra L Munger, Susan Finerty, Andrew J Morgan, Alberto Ascherio.   

Abstract

Previous infection with Epstein-Barr virus (EBV) and infectious mononucleosis are established multiple sclerosis (MS) risk factors, and elevated serum titers of anti-EBV nuclear antigen (anti-EBNA) antibodies in healthy adults are strongly correlated with future MS risk. In this prospective study, we investigated the association between EBV neutralizing antibodies and MS risk. MS risk tended to be higher in individuals with high titers of neutralizing antibodies compared to those with low titers (relative risk [RR] = 2.2, 95% confidence interval [CI] 0.97-5.1). This association was attenuated after adjustment for anti-EBNA1 IgG Ab titers (RR = 1.4, 95% CI 0.5-3.5). This preliminary finding warrants further study in a larger population.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22291034      PMCID： PMC3433051          DOI： 10.1177/1352458511433920

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  8 in total

Review 1.  Environmental risk factors for multiple sclerosis. Part I: the role of infection.

Authors:  Alberto Ascherio; Kassandra L Munger
Journal:  Ann Neurol       Date:  2007-04       Impact factor: 10.422

2.  Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.

Authors:  A Ascherio; K L Munger; E T Lennette; D Spiegelman; M A Hernán; M J Olek; S E Hankinson; D J Hunter
Journal:  JAMA       Date:  2001-12-26       Impact factor: 56.272

3.  Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.

Authors:  G R Nemerow; C Mold; V K Schwend; V Tollefson; N R Cooper
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

Review 4.  Epstein-barr virus infection and multiple sclerosis: a review.

Authors:  Alberto Ascherio; Kassandra L Munger
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-06       Impact factor: 4.147

5.  Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis.

Authors:  J W Lindsey; L M Hatfield; T Vu
Journal:  Eur J Neurol       Date:  2010-10       Impact factor: 6.089

6.  Primary infection with the Epstein-Barr virus and risk of multiple sclerosis.

Authors:  Lynn I Levin; Kassandra L Munger; Eilis J O'Reilly; Kerstin I Falk; Alberto Ascherio
Journal:  Ann Neurol       Date:  2010-06       Impact factor: 10.422

7.  Indirect measurement of Epstein-Barr virus neutralising antibodies by ELISA.

Authors:  A D Wilson; A J Morgan
Journal:  J Virol Methods       Date:  1998-07       Impact factor: 2.014

8.  Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.

Authors:  Etienne M Sokal; Karel Hoppenbrouwers; Corinne Vandermeulen; Michel Moutschen; Philippe Léonard; Andre Moreels; Michèle Haumont; Alex Bollen; Françoise Smets; Martine Denis
Journal:  J Infect Dis       Date:  2007-12-15       Impact factor: 5.226
  8 in total
  6 in total

Review 1.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

2.  Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Authors:  Charles Pierrot-Deseilligny; Jean-Claude Souberbielle
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

3.  B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanisms.

Authors:  Heather L Wilson
Journal:  Biologics       Date:  2012-05-07

4.  The risk of smoking on multiple sclerosis: a meta-analysis based on 20,626 cases from case-control and cohort studies.

Authors:  Peng Zhang; Rui Wang; Zhijun Li; Yuhan Wang; Chunshi Gao; Xin Lv; Yuanyuan Song; Bo Li
Journal:  PeerJ       Date:  2016-03-15       Impact factor: 2.984

5.  Breastfeeding, previous Epstein-Barr virus infection, Enterovirus 71 infection, and rural residence are associated with the severity of hand, foot, and mouth disease.

Authors:  Yaping Li; Shuangsuo Dang; Huiling Deng; Wenjun Wang; Xiaoli Jia; Ning Gao; Mei Li; Jun Wang
Journal:  Eur J Pediatr       Date:  2013-01-24       Impact factor: 3.860

6.  Evaluation of reactive Epstein-Barr Virus (EBV) in Iranian patient with different subtypes of multiple sclerosis (MS).

Authors:  Nourollah Ramroodi; Abbas Ali Niazi; Nima Sanadgol; Zohre Ganjali; Vida Sarabandi
Journal:  Braz J Infect Dis       Date:  2013-03-05       Impact factor: 3.257
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.